However, though in a mouse model of breast cancer, it has been reported that a rebound effect following inhibition of CCL2 pathway resulted in the recruitment of monocytes/macrophages into the tumour and enhancement of lung metastasis [124]; different antibodies targeting CCL2 have been entered phase I and II clinical trials. The gene discussed is CCL2; the disease is breast carcinoma.